Table I.
Association between TFAP2A and the clinicopathological parameters of patients with cervical cancer.
| Expression level of TFAP2A | |||
|---|---|---|---|
|
|
|||
| Clinicopathological characteristics | Low | High | P-value |
| Total cases, n (%) | 46 | 45 | |
| Age, years | 0.159 | ||
| ≤55 | 24 (26.4%) | 30 (33.0%) | |
| >55 | 22 (24.2%) | 15 (16.5%) | |
| Underlying diseases | 0.763 | ||
| Yes | 35 (38.5%) | 33 (36.3%) | |
| No | 11 (12.1%) | 12 (13.2%) | |
| Pregnancy | 0.599 | ||
| ≤3 | 22 (24.1%) | 24 (26.4%) | |
| >3 | 24 (26.4%) | 21 (23.1%) | |
| Childbirth | 0.014 | ||
| ≤2 | 27 (30.0%) | 37 (40.7%) | |
| >2 | 19 (20.9%) | 8 (8.8%) | |
| CEA (ng/ml) | 0.526 | ||
| ≤5 | 40 (45.0%) | 39 (43.9%) | |
| >5 | 4 (4.5%) | 6 (6.7%) | |
| CA125 (U/ml) | 0.080 | ||
| ≤35 | 38 (43.2%) | 44 (50.0%) | |
| >35 | 5 (5.7%) | 1 (1.1%) | |
| HE4 (pmol/ml) | 0.044 | ||
| ≤60.5 | 32 (41.6%) | 25 (50.6%) | |
| >60.5 | 6 (7.8%) | 14 (18.2%) | |
| SCC (ng/ml) | 0.193 | ||
| ≤1.5 | 6 (8.0%) | 12 (16.0%) | |
| >1.5 | 29 (38.7%) | 28 (37.3%) | |
| FIGO stage | 0.043 | ||
| Ib-IIa | 39 (43.3%) | 31 (34.4%) | |
| IIb-IV | 6 (6.7%) | 14 (15.6%) | |
| HPV infection | 0.013 | ||
| Negative | 12 (13.2%) | 3 (3.3%) | |
| Positive | 34 (37.4%) | 42 (46.2%) | |
| Lymph node metastasis | 0.534 | ||
| Yes | 5 (5.8%) | 7 (8.1%) | |
| No | 38 (44.2%) | 36 (41.9%) | |
| Vascular invasion | 0.006 | ||
| Yes | 18 (28.1%) | 8 (12.5%) | |
| No | 13 (20.3%) | 25 (39.1%) | |
| Nerve Violation | 0.772 | ||
| Yes | 18 (34.6%) | 20 (38.5%) | |
| No | 6 (11.5%) | 8 (15.4%) | |
TFAP2A, transcription factor AP-2 alpha; SCC, squamous cell carcinoma; CEA, carcinoembryonic antigen; HE4, human epididymis protein 4.